Berman Capital Advisors’s Rubius Therapeutics, Inc RUBY Stock Holding History

Berman Capital Advisors’s Portfolio RUBY Stock Details RUBY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$1K	Buy	+59	New	+$1.28K	﹤0.01%	2026

Other funds holding RUBY

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Berman Capital Advisors's RUBY Position: Q3 2021 in Review

Berman Capital Advisors opened a new position in Rubius Therapeutics, Inc (RUBY) in Q3 2021: 59 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #2026 among its holdings.

105 funds tracked by Wall St. Rank hold RUBY as of Q3 2021.

Berman Capital Advisors held 59 shares of Rubius Therapeutics, Inc worth $1K as of Q3 2021.
Rubius Therapeutics, Inc was a new Berman Capital Advisors position in Q3 2021.
Rubius Therapeutics, Inc made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #2026 holding.
105 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.